Compare Global E Online Ltd (GLBE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Novo Nordisk A/S — how do they compare? Global E Online Ltd trades at $40.37 (market cap $6.75B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 24.5× Global E Online Ltd's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Novo Nordisk A/S for 116 Days on average.
| GLBE | NVO | |
|---|---|---|
Market Cap | $6.75B | $165.31B |
Volume | 1,468,708 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $63.98 |
52-Week Low | $27.54 | $35.29 |
Typical Hold Time | 21 Days | 116 Days |
Enterprise Value | $6.24B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.25, up 3.31% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth of 39% year-over-year. Recent news includes the appointment of a new Chief Revenue Officer and significant insider selling by executives.
The outlook is positive, supported by strong revenue growth, expanding margins, and a high analyst buy rating. Key risks include elevated valuation multiples, insider selling pressure, and dependence on e-commerce market conditions. The stock offers potential upside to the consensus price target of $48.86.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
